#Merck #SpringWorksTherapeutics #Ezmekly #mirdametinib #NF1PN #plexiformneurofibromas #neurofibromatosistype1 #NF1 #NF1PNpatients #NationalReferenceCenterforAdultPatientswithNeurofibromatosis #phase2bclinicaltrial #ReNeutrial #NFpatients #RareTumors
pharmatimes.com/news/ezmekly...
pharmatimes.com/news/ezmekly...
Ezmekly becomes first approved EU therapy for NF1-PN in children and adults - PharmaTimes
EC grants conditional marketing authorisation to Merck and SpringWorks Therapeutics
pharmatimes.com
July 24, 2025 at 9:29 AM
#Merck #Ezmekly #NHSuse #HEOR #MarketAccess #MerckKGaA #Neurofibromatosis #NF1 #NFItherapy #rarediseases #Reimbursement #NICE #oralMEKinhibitor #plexiformneurofibromas #PN #PNassociatedwithNF1 #paediatrics #MHRA #NICEfinaldraftguidance #paediatricNF1patients #ReNeutrial #PNlesions
zurl.co/8MUea
zurl.co/8MUea
Merck rare tumour drug Ezmekly backed for NHS use
Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
pharmaphorum.com
September 7, 2026 at 12:13 PM